Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thrombosis 2Venous Thromboembolism 2Neoplasms 2Pulmonary Embolism 1Hemorrhage 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13Cytarabine 9Dalteparin 8Rivaroxaban 7Daunorubicin 7apixaban 6Etoposide 6Methotrexate 5Idarubicin 5Heparin, Low-Molecular-Weight 5Cyclophosphamide 5emicizumab 4Tinzaparin 4Thioguanine 4Mitoxantrone 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Enoxaparin 4pegfilgrastim 3hetrombopag 3epoetin beta 3Saline Solution 3Radiotherapy 3Hydrocortisone 3Erythropoietin 3Dexamethasone 3Aspirin 3Asparaginase 3telapristone acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × bemiparin × Classical hematology × Clear all
NCT01164046 2014-12-03

Longheva

University Medical Center Groningen

Phase 3 Terminated
56 enrolled
Classical hematology

Neoplasms, Venous Thrombosis, Venous Thromboembolism

NCT00219973 2010-04-28

CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

Rovi Pharmaceuticals Laboratories

Phase 3 Completed
526 enrolled
Classical hematology

Hemorrhage, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡